Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.
about
Immunogenicity of protein therapeutics: The key causes, consequences and challengesTheranostic applications of antibodies in oncology.Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer.177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice.89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.86Y based PET radiopharmaceuticals: radiochemistry and biological applicationsDosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review.(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.Functional imaging for prostate cancer: therapeutic implications.Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates.Targeting the prostate-specific membrane antigen for prostate cancer therapy.Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancerGeneral overview of radioimmunotherapy of solid tumors.High resolution digital autoradiographic and dosimetric analysis of heterogeneous radioactivity distribution in xenografted prostate tumors.Relevance of radiobiological concepts in radionuclide therapy of cancer.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological diseaseEarly side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.PSMA PET and Radionuclide Therapy in Prostate Cancer.Metal-Based PSMA Radioligands.177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry.PSMA as a target for radiolabelled small molecules.Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.PSMA Theranostics: Current Status and Future Directions.A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients.Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine
P2860
Q24633296-C5BF1CEA-747A-4CCB-AA7B-A24280304DFEQ27693293-DCED8D5C-F94E-4D61-B275-7F56A01D1548Q30354652-CDA7FA7C-58F2-46AA-99E7-9BF2BA1A80C9Q33301860-4582F0DC-A626-486A-9CBA-894BEE37172CQ33645821-46902DED-BE96-4AC6-944B-0492FF858835Q33821017-76BBFFCF-0DFA-4201-B825-3307D1560648Q34389457-09F910BE-3B21-4297-B5B5-0D0F9A1E2404Q35250409-41624D90-B915-4496-B827-ADF6C1CFE97CQ35582104-8309CBA0-4BA5-464C-839B-EF9F296144A3Q35877470-682BDB24-95E0-46DF-A731-E4194CA6610AQ36128629-A8F367CE-D508-4BA0-97E6-323ECF6AEEF7Q36160805-DA3AF9C7-A240-4533-B175-2BAAC9D73DF3Q37773273-B1A6A839-6467-4C3A-8379-22AF89253ACDQ37972920-04D50634-A243-48B7-87D5-31F9D6C13572Q38103579-60E4C4E5-AF65-44B2-8849-07F0998AC4E8Q38728044-5CCB5BF1-44B1-452D-B17C-B4980CA844BEQ38751028-0BB81F4B-9D49-4C56-A08C-58837B7B8806Q38831232-5F46258F-918D-4EAA-B9B8-EAB035938BD7Q38861197-3907490E-646E-4EAA-BB9A-EFC37E99302CQ39003089-1EF5ECFB-C588-4D40-821E-1870EBFCC671Q39198527-91210A24-267F-4D8F-BBE6-E4DEB6E49426Q39632700-691CFB95-84E5-414A-B4FD-CC7C87002F38Q39808317-7FEB6FEF-08D6-4776-8CB0-E2281DAB8B5DQ40529844-E2721878-D4F9-4801-BA17-2C9975EF090FQ42105089-26F357B5-81B2-4A1D-93A7-0BE6FDE7C160Q43177005-E06F7FD7-B2AC-4182-8181-6049064C2C38Q51743830-F5A3AC34-2623-485C-B66D-25A4F7F77058Q55023828-1D9309A4-9F6F-49BF-9238-1128E6B1309CQ55415632-A169E9CA-0E7E-424F-8CBB-D8D112872B6CQ57107703-3B7266F2-DCA3-4AEB-BAA6-F2A3DE42D493
P2860
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Radioimmunotherapy of prostate ...... e treatments on myelotoxicity.
@ast
Radioimmunotherapy of prostate ...... e treatments on myelotoxicity.
@en
type
label
Radioimmunotherapy of prostate ...... e treatments on myelotoxicity.
@ast
Radioimmunotherapy of prostate ...... e treatments on myelotoxicity.
@en
prefLabel
Radioimmunotherapy of prostate ...... e treatments on myelotoxicity.
@ast
Radioimmunotherapy of prostate ...... e treatments on myelotoxicity.
@en
P2093
P1476
Radioimmunotherapy of prostate ...... e treatments on myelotoxicity.
@en
P2093
David M Nanus
Lale Kostakoglu
Mathew I Milowsky
Neil H Bander
Shankar Vallabhajosula
Stanley J Goldsmith
P304
7195s-7200s
P356
10.1158/1078-0432.CCR-1004-0023
P407
P433
P577
2005-10-01T00:00:00Z